In Ae Park

In Ae Park

Auto-generated profile, based on publicly available information

In Ae Park

Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2010 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JKJi-Hyun Kwon
Ji-Hyun Kwon
YKYu Jung Kim
Yu Jung Kim
KLKeun-Wook Lee
Keun-Wook Lee
DODo-Youn Oh
Do-Youn Oh
SPSo-Yeon Park
So-Yeon Park
SHSung Whan Ha
Sung Whan Ha
Background: Whether a systemic adjuvant treatment is needed is an area of controversy in patients with node-negative early breast cancer with tumor size of ≤1 cm, including T1mic. Methods: We performed a retrospective analysis of clinical and pathology data of all consecutive patients with node-negative T1mic, T1a, and T1b invasive ductal carcinoma who received surgery between Jan 2000 and Dec 2006. The recurrence free survival (RFS) and risk factors for recurrence were identified. Results: Out of 3889 patients diagnosed with breast cancer, 375 patients were enrolled (T1mic:120, T1a:93, T1b:162). Median age at diagnosis was 49. After a median follow up of 60.8 months, 12 patients developed recurrences (T1mic:4 (3.3%), T1a:2 (2.2%), T1b:6 (3.7%)), with a five-year cumulative RFS rate of 97.2%. Distant recurrence was identified in three patients. Age younger than 35 years (HR 4.91; 95% CI 1.014-23.763, p = 0.048) and triple negative disease (HR 4.93; 95% CI 1.312-18.519, p = 0.018) were significantly associated with a higher rate of recurrence. HER2 overexpression, Ki-67, and p53 status did not affect RFS. Conclusions: Prognosis of node-negative breast cancer with T1mic, T1a and T1b is excellent, but patients under 35 years of age or with triple negative disease have a relatively high risk of recurrence.

13 July 2011 in Cancer Science
Verified
Journal Article
Open access
PDF file
MBMin Sun Bae
Min Sun Bae
WHWonshik Han
Wonshik Han
HKHye Ryoung Koo
Hye Ryoung Koo
NCNariya Cho
Nariya Cho
JCJung Min Chang
Jung Min Chang
WMWoo Kyung Moon
Woo Kyung Moon
Screening ultrasound (US) can increase the detection of breast cancer. However, little is known about the clinicopathologic characteristics of breast cancers detected by screening US. A search of the database for patients with breast cancer yielded a dataset in 6837 women who underwent breast surgery at Seoul National University Hospital (Korea). Of 6837 women, 1047 were asymptomatic and had a non-palpable cancer. Two hundred fifty-four women with 256 cancers detected by US (US-detected cancer) and 793 women with 807 cancers detected by mammography (MG-detected cancer) were identified. The imaging, clinicopathologic, and molecular data were reviewed. Univariate and multivariate analyses were carried out. Women with US-detected cancer were younger and were more likely to undergo breast-conserving surgery and to have node-negative invasive cancer (P < 0.0001). By multivariate analysis, the significant independent characteristics were tumor size, mammographic density, final assessment category according to the American College of Radiology Breast Imaging Reporting and Data System, progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and molecular subtype. Compared to tumors that were >2 cm in size, tumors that were ≤1 cm in size were 2.2-fold more likely to be US-detected cancers (P = 0.02). Compared to the luminal A subtype tumors (estrogen receptor [ER]+, PR+, HER2−), luminal B subtype tumors (ER+, PR+, HER2 + ) were less likely to be in the US-detected cancer group (P < 0.01). Women with dense breasts were more likely to have US-detected cancer (P < 0.01) versus those with non-dense breasts. Screening US-detected cancers were less likely to be diagnosed as category 5 instead of category 4 (P < 0.01). In conclusion, women with US-detected breast cancer are more likely to have small-sized invasive cancer and more likely associated with the luminal A subtype. (Cancer Sci 2011; 102: 1862–1867)

15 January 2015 in Journal of Pathology and Translational Medicine
Verified
Journal Article
Open access
PDF file
HBHae Woon Baek
Hae Woon Baek
MPMin Jee Park
Min Jee Park
YRYe-Young Rhee
Ye-Young Rhee
KLKyoung Bun Lee
Kyoung Bun Lee
MKMin A Kim
Min A Kim
IPIn Ae Park
In Ae Park
Endoscopic ultrasound-guided fine needle aspiration cytology (EUS-FNAC) is currently the most commonly used procedure for obtaining cytologic specimens of the pancreas. It is accurate, minimally invasive, safe and cost-effective. However, there is discrepancy between cytological and surgical diagnoses. This study was aimed at evaluating the diagnostic accuracy of EUS-FNAC of the pancreas. We performed a retrospective review of 191 cases of pancreatic lesions initially diagnosed by EUS-FNAC with subsequent histological diagnosis between 2010 and 2012 in the Department of Pathology, Seoul National University Hospital. Cytologic and surgical diagnoses were categorized into five groups: negative, benign, atypical, malignant, and insufficient for diagnosis. Subsequently, 167 cases with satisfactory yield in both surgical and cytology specimens were statistically analyzed to determine correlations with diagnosis. In comparison to surgical diagnoses, cytologic diagnoses were true-positive in 103 cases (61.7%), true-negative in 28 cases (16.8%), false-positive in 9 cases (5.4%), and false-negative in 27 cases (16.1%). The diagnostic accuracy was 78.4%, sensitivity was 79.2%, and specificity was 75.7%. The positive predictive value was 92.0%, and negative predictive value was 50.9%. EUS-FNAC has high accuracy, sensitivity, specificity and positive predictive value. Overcoming the limitations of EUS-FNAC will make it a useful and reliable diagnostic tool for accurate evaluation of pancreatic lesions.

1 January 2013 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
HLHo-Chang Lee
Ho-Chang Lee
HKHyoungsuk Ko
Hyoungsuk Ko
HSHyesil Seol
Hyesil Seol
DNDong-Young Noh
Dong-Young Noh
WHWonshik Han
Wonshik Han
IPIn Ae Park
In Ae Park
Lee HC, et al. J Breast Cancer. 2013 Dec;16(4):395-403. https://doi.org/10.4048/jbc.2013.16.4.395

1 January 2011 in Korean Journal of Otorhinolaryngology-Head and Neck Surgery
Verified
Journal Article
Closed access
PDF file
KYKa Hee Yi
Ka Hee Yi
YPYoung Joo Park
Young Joo Park
SKSung-Soo Koong
Sung-Soo Koong
JKJung-Han Kim
Jung-Han Kim
DNDong Gyu Na
Dong Gyu Na
BCBo Youn Cho
Bo Youn Cho

21 July 2016 in BMC Cancer
Verified
Journal Article
Open access
PDF file
YYYaewon Yang
Yaewon Yang
SISeock-Ah Im
Seock-Ah Im
BKBhumsuk Keam
Bhumsuk Keam
KLKyung-Hun Lee
Kyung-Hun Lee
TKTae-Yong Kim
Tae-Yong Kim
DNDong-Young Noh
Dong-Young Noh
Neoadjuvant chemotherapy (NAC) is a standard treatment for stage II/III breast cancer patients, and response to NAC is a useful prognostic marker. Since its introduction, 6–8 cycles of NAC has become the standard regimen to improve the outcome of these patients. The purpose of this study is to evaluate the prognostic impact of the American Joint Committee on Cancer (AJCC) response criteria and this tool’s usefulness in four different breast cancer subtypes. We conducted a retrospective cohort study of clinical stage II/III breast cancer patients who received NAC of more than 6 cycles. Response after NAC and the clinicopathological factors were reviewed. AJCC response criteria for NAC were adopted from the AJCC Manual, 7th edition: complete response (CR), partial response (PR), and no response (NR). A total of 183 patients were enrolled; 22 (12.0 %), 123 (67.2 %), and 38 (20.8 %) patients showed CR, PR, and NR, respectively. The AJCC response was significantly associated with relapse-free survival (RFS) (P < 0.001), whereas pathologic CR (pCR), the current gold standard for response evaluation for NAC, was not (P = 0.140). AJCC response was a significant prognostic factor for RFS in all four breast cancer subtypes, namely luminal A (P = 0.006), luminal B (P = 0.001), HER-2 enriched (P = 0.039), and triple-negative breast cancer (P = 0.035). The AJCC response criteria represent a simple and easily reproducible tool for response evaluation of NAC patients and a useful clinical prognostic marker for RFS. These criteria also have a prognostic impact in all four breast cancer subtypes, including luminal A in which pCR has a limited role.